Journal of Pain & Palliative Care Pharmacotherapy最新文献

Efficacy of Lavender Oil as an Adjunctive Treatment for Patients with Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Trial. 薰衣草油作为骨关节炎患者辅助治疗的疗效：一项随机、双盲、安慰剂对照试验

IF 0.9

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2025-04-07 DOI: 10.1080/15360288.2025.2485202

Mitra Abbasifard, Mehrnaz Aghaabasi, Zahra Kamiab, Mahmood Kahnooji, Gholamreza Bazmandegan, Neda Mohamadi

{"title":"Efficacy of Lavender Oil as an Adjunctive Treatment for Patients with Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Trial.","authors":"Mitra Abbasifard, Mehrnaz Aghaabasi, Zahra Kamiab, Mahmood Kahnooji, Gholamreza Bazmandegan, Neda Mohamadi","doi":"10.1080/15360288.2025.2485202","DOIUrl":"https://doi.org/10.1080/15360288.2025.2485202","url":null,"abstract":"Patients with knee osteoarthritis (OA) experience decline in social and physical abilities. Lavender is a promising option. To determine the clinical efficacy of lavender oil in comparison with Piroxicam gel (PG) for the treatment of knee OA. A double-blind trial with 90 patients utilized random blocks to divide them into three groups including the lavender oil group, the PG group, and the control group for treatment comparison. The Visual Analogue Scale (VAS) and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) were used to measure aspects of osteoarthritis, particularly physical function, pain, and stiffness. Control group had no change in VAS pain scores. Lavender oil and PG reduced scores after one month, but remained unchanged after two months. The VAS scores of the lavender oil group exhibited a significant reduction from 5.37 ± 0.68 to 3.00 ± 0.64, while PG decreased VAS score from 5.45 ± 0.98 to 3.62 ± 1.26 (p < 0.001). There was no significant difference between the two treatment groups. Altogether, Lavender oil has a similar effect as PG on pain severity and physical function in patients with knee OA. Lavender oil is recommended as an effective natural therapeutic agent and safe complementary treatment for knee OA.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"1-8"},"PeriodicalIF":0.9,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143795659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Beyond the Prescription: Addressing Accessibility, Stigma, and Education in Buprenorphine Therapy. 超越处方：解决丁丙诺啡治疗的可及性、污名和教育问题。

IF 0.9

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2025-04-07 DOI: 10.1080/15360288.2025.2488845

Jonathan James O Canete

引用次数: 0

A Systematic Review and Meta-Analysis of The Efficacy of Endoscopic Ultrasound Guided Celiac Plexus Blocks for Chronic Pancreatitis Pain. 超声内镜引导下腹腔神经丛阻滞治疗慢性胰腺炎疼痛疗效的系统评价和meta分析。

IF 0.9

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2025-04-01 DOI: 10.1080/15360288.2025.2479481

Luke Kar Man Chan, Tanish Rao, Paolo Masangcay, Samuel Chia Lin Kuo, Tai-Tak Wan

{"title":"A Systematic Review and Meta-Analysis of The Efficacy of Endoscopic Ultrasound Guided Celiac Plexus Blocks for Chronic Pancreatitis Pain.","authors":"Luke Kar Man Chan, Tanish Rao, Paolo Masangcay, Samuel Chia Lin Kuo, Tai-Tak Wan","doi":"10.1080/15360288.2025.2479481","DOIUrl":"https://doi.org/10.1080/15360288.2025.2479481","url":null,"abstract":"Chronic pancreatitis is a globally prevalent progressive disease, with pain affecting up to 90% of patients, significantly impairing quality of life and leading to high rates of disability, hospitalizations, and opioid dependence. Pain management is crucial in treating chronic pancreatitis, with endoscopic ultrasound-guided celiac plexus block (EUS-CPB) recognized as an interventional option. This systematic review and meta-analysis, following PRISMA guidelines, synthesized data from 12 studies (5 randomized control trials and 7 observational) on the efficacy of EUS-CPB in managing chronic pancreatitis pain. The overall analysis revealed a significant pain relief proportion of 0.64 (n=612) with moderate heterogeneity. Subgroup analyses revealed a proportion of 0.72 in RCTs and 0.59 in observational studies. Common complications included diarrhea and exacerbation of abdominal pain, with no reported mortality. Despite variations in efficacy due to study heterogeneity and patient differences, the findings suggest EUS-CPB as a safe and effective option, with effects lasting weeks to months. Recent studies have demonstrated the applicability of EUS-CPB across ethnically diverse and pediatric populations. However, limitations including small sample sizes and study variability highlight the need for personalized treatment approaches. Future larger randomized sham-controlled trials are recommended to better assess the duration of pain relief and impact on opioid use.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"1-12"},"PeriodicalIF":0.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of Prophylactic Dual Histamine Blockade on Filgrastim-Induced Bone Pain in Female Cancer Patients: Single Institutional Analysis. 预防性双组胺阻断对非格昔汀引起的女性癌症患者骨痛的影响：单一机构分析。

IF 0.9

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2025-03-27 DOI: 10.1080/15360288.2025.2482884

Noor Ul Ain Azam, Fauzia Abdus Samad, Abdus Samad Syed, Asif Riaz Khan, Aalia Mushtaq, Faraz Saif

{"title":"Effect of Prophylactic Dual Histamine Blockade on Filgrastim-Induced Bone Pain in Female Cancer Patients: Single Institutional Analysis.","authors":"Noor Ul Ain Azam, Fauzia Abdus Samad, Abdus Samad Syed, Asif Riaz Khan, Aalia Mushtaq, Faraz Saif","doi":"10.1080/15360288.2025.2482884","DOIUrl":"https://doi.org/10.1080/15360288.2025.2482884","url":null,"abstract":"Bone pain is the commonest side-effect faced by cancer patients receiving granulocyte colony stimulating factor (G-CSF) therapy for the primary or secondary prevention of febrile neutropenia. We conducted a prospective quasi-experimental study at our setup to see the efficacy of dual histamine blockade (combined H1 and H2 receptor blockers) for preventing G-CSF-induced bone pain. Adult female patients with solid tumors who had received filgrastim for the primary prophylaxis of febrile neutropenia and met our inclusion criteria, were enrolled (n = 119). This population was analyzed for the development of significant bone pain 24 h after the administration of Filgrastim. Significant bone pain in our study was defined as emergence of new onset pain measuring ≥4 on 11-point Numerical rating scale (NRS) or at least ≥ 2-point increase in score when compared to the baseline pain (if any). Those patients who experienced significant bone pain (n = 47) were given Loratadine 10 mg and Famotidine 20 mg orally half an hour before the next filgrastim administration. Pain assessment was done 24 h after Filgrastim administration, using NRS and data was analyzed. The mean NRS score in our patients after administration of filgrastim was 6.87 ± 1.055. Most of these patients (n = 34 i.e 72%) experienced relief in bone pain after dual histamine blockade use. The mean NRS score following the use of dual antihistamines was 4.36 ± 1.870. The NRS score improved by a mean of 2.51 after using dual histamine blockade, which was statistically significant (p-value= 0.0005). We propose that dualhistamine blockade may prove to be an effective option for prophylaxis of G-CSF-induced-bone-pain. Randomized control trials on larger and more diverse patient populations are required to reinforce the findings.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"1-10"},"PeriodicalIF":0.9,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143720056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Improving Support for Family Caregivers in Palliative Care: Insights and Policy Implications. 改善对姑息治疗家庭照顾者的支持：见解和政策意义。

IF 0.9

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2025-03-21 DOI: 10.1080/15360288.2025.2480226

John Patrick C Toledo

引用次数: 0

Comparison of Risk Prediction Models to Estimate Opioid-Induced Respiratory Depression, Oversedation, and Overdose in Patients with Cancer. 评估癌症患者阿片类药物引起的呼吸抑制、过度镇静和过量用药风险预测模型的比较

IF 0.9

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2025-03-20 DOI: 10.1080/15360288.2025.2481186

Norint P Tung, Parker K Kaleo, Eric J Roeland, Joseph D Ma

{"title":"Comparison of Risk Prediction Models to Estimate Opioid-Induced Respiratory Depression, Oversedation, and Overdose in Patients with Cancer.","authors":"Norint P Tung, Parker K Kaleo, Eric J Roeland, Joseph D Ma","doi":"10.1080/15360288.2025.2481186","DOIUrl":"https://doi.org/10.1080/15360288.2025.2481186","url":null,"abstract":"Numerous opioid-induced respiratory depression (OIRD), oversedation, and overdose prediction models exist to quantify a probability or estimate risk severity for a future event. The primary aim was to determine OIRD, oversedation, and overdose risk severity (i.e., low, moderate, and high) and agreement of risk severity between three previously published prediction models. This single-center, retrospective analysis evaluated 134 patients with cancer. Sixty-five (49%) patients were Caucasian. Forty-three (32%) patients were diagnosed with gastrointestinal cancer. Predictive factors from prediction models were concurrent sedating medication (n = 119, 89%), female sex (n = 85, 63%), a mental health diagnosis (n = 68, 51%), and antidepressant use (n = 55, 41%). For most patients, risk severity varied between moderate to high risk. Risk class severity was significantly different between prediction models (p ≤ 0.05). Frequencies of risk severity agreement between all three prediction models, between two prediction models, and no agreement was 16% (n = 22), 69% (n = 93), and 14% (n = 19), respectively. Additional research is needed to evaluate model calibration to increase OIRD, oversedation, and overdose prediction model validity and generalizability for future clinical implementation.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"1-9"},"PeriodicalIF":0.9,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of Cannabis-Based Medicinal Product Formulations for Fibromyalgia: A Cohort Study. 比较治疗纤维肌痛的大麻药用产品配方：队列研究。

IF 0.9

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2025-03-01 Epub Date: 2024-10-17 DOI: 10.1080/15360288.2024.2414073

Surya Sridharan, Simon Erridge, Carl Holvey, Ross Coomber, Wendy Holden, James J Rucker, Michael Platt, Mikael H Sodergren

{"title":"Comparison of Cannabis-Based Medicinal Product Formulations for Fibromyalgia: A Cohort Study.","authors":"Surya Sridharan, Simon Erridge, Carl Holvey, Ross Coomber, Wendy Holden, James J Rucker, Michael Platt, Mikael H Sodergren","doi":"10.1080/15360288.2024.2414073","DOIUrl":"10.1080/15360288.2024.2414073","url":null,"abstract":"This cohort study aims to assess the outcomes of fibromyalgia patients enrolled in the UK Medical Cannabis Registry prescribed a homogenous selection of cannabis-based medicinal products (CBMPs). A cohort study of fibromyalgia patients treated with oils (Adven®, Curaleaf International, UK), dried flower (Adven®, Curaleaf International, UK) or both CBMPs was performed. Primary outcomes were changes from baseline at 1, 3, 6 and 12 months in validated patient-reported outcome measures. Secondary outcomes included descriptive analysis of adverse events. One hundred and forty-eight participants were treated with oils (n = 77; 52.03%), dried flower (n = 14; 9.46%) or both (n = 57; 38.51%). Improvements in the generalized anxiety disorder-7 questionnaire, single-item sleep quality scale, fibromyalgia symptom severity score and EQ-5D-5L Index values were observed at each follow up period compared to baseline (p < 0.050). Thirty-six (24.32%) patients experienced 648 adverse events. Improvements were observed across all primary outcomes with no differences observed across different formulations of CBMPs. Adverse events were reported by one-quarter of participants and were more likely to reported by cannabis naïve patients. This present work through focusing on a homogeneous group of CBMPs can help inform randomized controlled trials after observing signals of improvement associated with a specific cultivar of CBMPs.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"24-37"},"PeriodicalIF":0.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142468187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Effectiveness of Tramadol in Pain Relief in Chronic Diseases: A Review Based on Clinical Trials. 曲马多缓解慢性病疼痛的疗效：基于临床试验的综述

IF 0.9

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2025-03-01 Epub Date: 2024-10-23 DOI: 10.1080/15360288.2024.2411239

Kosar Seidmohammadi, Hoda Haghshenas, Sara Moghaddam, Hossein Kargar Jahromi, Hamed Delam

{"title":"The Effectiveness of Tramadol in Pain Relief in Chronic Diseases: A Review Based on Clinical Trials.","authors":"Kosar Seidmohammadi, Hoda Haghshenas, Sara Moghaddam, Hossein Kargar Jahromi, Hamed Delam","doi":"10.1080/15360288.2024.2411239","DOIUrl":"10.1080/15360288.2024.2411239","url":null,"abstract":"Tramadol is a synthetic opioid with a central effect from the aminocyclohexanol group, which has two main mechanisms of action, including as a weak agonist of opioid receptors and as a norepinephrine and serotonin reuptake inhibitor. The present study presents a review based on clinical trials designed in 2023. In July 2023, six international databases, including Medline/PubMed, ProQuest, Scopus, EMBASE, Google Scholar, and ISI (Web of Science), were searched and 58 articles were included in the study. The results of most studies showed that tramadol can be used as an analgesic drug, although in some studies it was shown that tramadol is not therapeutically superior in reducing pain compared to other treatments. Also, complications related to this treatment have been reported in some studies. Physicians should consider these factors to prevent drug toxicity, poor pain relief, use disorder in patients, and unpredictable complications. It should be noted that there is not enough evidence to support the long-term effectiveness of tramadol, but this argument also extends to nonopioid and other types of opioid analgesics, and the lack of long-term trials is due to regulatory and ethical issues. Although opioids can cause addiction when used for a long time, tramadol has a reasonable safety profile. According to the patient's condition and the clinical judgment of the medical professional, tramadol can be prescribed for patients, but the consequences of its use must be considered and a personalized treatment algorithm should be selected if the benefits outweigh the risks of the drug.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"139-161"},"PeriodicalIF":0.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142502372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating the Impact of Buprenorphine on Depressive Symptoms Among Veterans with Chronic Pain. 评估丁丙诺啡对慢性疼痛退伍军人抑郁症状的影响。

IF 0.9

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2025-03-01 Epub Date: 2024-11-22 DOI: 10.1080/15360288.2024.2427877

Anne V Cetto, Michael W Chandler, Neil K Shah, Lisa L Luciani, Jacob Painter

{"title":"Evaluating the Impact of Buprenorphine on Depressive Symptoms Among Veterans with Chronic Pain.","authors":"Anne V Cetto, Michael W Chandler, Neil K Shah, Lisa L Luciani, Jacob Painter","doi":"10.1080/15360288.2024.2427877","DOIUrl":"10.1080/15360288.2024.2427877","url":null,"abstract":"Buprenorphine has demonstrated benefit for acute and chronic pain and various psychiatric disorders. However, many studies evaluating buprenorphine's effect on psychiatric conditions are not specific to the chronic pain population. This retrospective study was conducted to assess the impact of buprenorphine on depressive symptoms in patients with chronic pain at a Veterans Affairs healthcare facility. Adults with chronic pain started on any formulation of buprenorphine or traditional opioid (non-buprenorphine opioid) with at least two depression screenings between May 1, 2016 and November 1, 2021 were included. The primary outcome was change in depressive symptoms, measured by Patient Health Questionnaire-9 (PHQ-9), from baseline to 6-18 months after starting therapy. Secondary outcomes included changes in Columbia-Suicide Severity Rating Scale and mental health services utilization. Twenty-one patients were included. Median baseline PHQ-9 in the buprenorphine and traditional opioid groups were 14 and 13, respectively. Median change in PHQ-9 was -5 in the buprenorphine group and -1.5 in the traditional opioid group. Compared to traditional opioids, buprenorphine was associated with a greater reduction in depressive symptoms among Veterans with chronic pain. Although this reduction met the threshold for clinically significant improvement, further investigation is needed to evaluate the clinical relevance of these findings.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"58-63"},"PeriodicalIF":0.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142693241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intrathecal Baclofen Pump Refill-Related Cardiac Arrest: A Case Report. 鞘内巴氯芬泵再充相关心脏骤停1例报告。

IF 0.9

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2025-03-01 Epub Date: 2024-11-28 DOI: 10.1080/15360288.2024.2433639

Mohammad Aldalahmeh, Elie Bou Sanayeh, Waleed Sadiq, Chapman Wei, Michel Chalhoub

引用次数: 0